1-3 of 3
Polina Kaplan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, MD, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, Christopher Chiu, PhD, Jianping Wang, Anupa Kudva, Rachel Kobos, MD, Susan Wroblewski, PhD, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD, Joan Bladé, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 156.
https://doi.org/10.1182/blood-2018-156
Published: 2018
Journal Articles

Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Maria-Victoria Mateos, Meletios A. Dimopoulos, Michele Cavo, MD, Kenshi Suzuki, Andrzej J. Jakubowiak, MD, Stefan Knop, MD, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, Doc,MD PhD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, Tomoaki Fujisaki, MD, Mamta Garg, MD, Christopher Chiu, PhD, Jianping Wang, Robin Carson, MD BA, Wendy Crist, BA, William Deraedt, Marie Nguyen, Ming Qi, Jesus F. San-Miguel, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): LBA-4.
https://doi.org/10.1182/blood.V130.Suppl_1.LBA-4.LBA-4
Published: 2017
Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta
Journal: Blood
Blood (2014) 124 (21): 4684.
https://doi.org/10.1182/blood.V124.21.4684.4684
Published: 2014